• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Advances in clinical trial design for development of new TB treatments: A call for innovation.新型结核病治疗方法研发的临床试验设计进展：呼吁创新。
PLoS Med. 2019 Mar 22;16(3):e1002769. doi: 10.1371/journal.pmed.1002769. eCollection 2019 Mar.
2
Advances in clinical trial design: Weaving tomorrow's TB treatments.临床试验设计的进展：编织明天的结核病治疗方法。
PLoS Med. 2020 Feb 27;17(2):e1003059. doi: 10.1371/journal.pmed.1003059. eCollection 2020 Feb.
3
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.新结核病治疗方案的研发：协调临床试验设计、产品注册要求和公共卫生指南。
PLoS Med. 2019 Sep 6;16(9):e1002915. doi: 10.1371/journal.pmed.1002915. eCollection 2019 Sep.
4
Emerging drugs for active tuberculosis.用于活动性结核病的新型药物。
Semin Respir Crit Care Med. 2008 Oct;29(5):552-9. doi: 10.1055/s-0028-1085706. Epub 2008 Sep 22.
5
Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.结核病：当前的治疗、诊断方法以及临床试验中的新型抗结核药物
Infect Disord Drug Targets. 2015;15(1):32-41. doi: 10.2174/1871526514666140923153329.
6
Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.结核分枝杆菌……我们能战胜它吗？2013年欧洲科学会议报告
Virulence. 2013 Aug 15;4(6):499-503. doi: 10.4161/viru.25397. Epub 2013 Jun 18.
7
Medicine. New TB drug promises shorter, simpler treatment.医学。新型结核病药物有望实现更短、更简便的治疗。
Science. 2004 Dec 10;306(5703):1872. doi: 10.1126/science.306.5703.1872.
8
[Tuberculosis].[结核病]
Dtsch Med Wochenschr. 2017 Dec;142(24):1838-1842. doi: 10.1055/s-0043-115427. Epub 2017 Sep 12.
9
Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?利福平单耐药结核病的检测与治疗方案：异烟肼的作用是什么？
Int J Tuberc Lung Dis. 2013 Jun;17(6):849-50. doi: 10.5588/ijtld.13.0066.
10
Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.结核病临床试验更新及当前抗结核药物组合。
Curr Med Chem. 2013;20(30):3785-96. doi: 10.2174/09298673113209990166.

引用本文的文献

1
Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes.早期微生物学标志物与肺结核治疗结局。
Ann Am Thorac Soc. 2023 Dec;20(12):1760-1768. doi: 10.1513/AnnalsATS.202302-144OC.
2
A comparison of clinical development pathways to advance tuberculosis regimen development.比较推进结核病治疗方案研发的临床开发途径。
BMC Infect Dis. 2022 Dec 9;22(1):920. doi: 10.1186/s12879-022-07846-w.
3
Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.痰液脂阿拉伯甘露聚糖（LAM）作为一种生物标志物来确定痰液分枝杆菌负荷：来自四个队列的综合数据的探索性和基于模型的分析。
BMC Infect Dis. 2022 Apr 2;22(1):327. doi: 10.1186/s12879-022-07308-3.
4
Screening Repurposed Antiviral Small Molecules as Antimycobacterial Compounds by a Lux-Based phoP Promoter-Reporter Platform.通过基于Lux的phoP启动子报告平台筛选重新利用的抗病毒小分子作为抗分枝杆菌化合物。
Antibiotics (Basel). 2022 Mar 9;11(3):369. doi: 10.3390/antibiotics11030369.
5
vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding.vCOMBAT：一种创建和可视化细菌抗生素靶标结合的计算模型的新工具。
BMC Bioinformatics. 2022 Jan 6;23(1):22. doi: 10.1186/s12859-021-04536-3.
6
The pipeline of new molecules and regimens against drug-resistant tuberculosis.针对耐药结核病的新分子和治疗方案研发流程
J Clin Tuberc Other Mycobact Dis. 2021 Nov 5;25:100285. doi: 10.1016/j.jctube.2021.100285. eCollection 2021 Dec.
7
The potential use of digital health technologies in the African context: a systematic review of evidence from Ethiopia.数字健康技术在非洲背景下的潜在应用：对来自埃塞俄比亚的证据进行的系统综述。
NPJ Digit Med. 2021 Aug 17;4(1):125. doi: 10.1038/s41746-021-00487-4.
8
Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.精准增强风险分层工具在结核病临床试验中选择最佳治疗持续时间的应用。
Am J Respir Crit Care Med. 2021 Nov 1;204(9):1086-1096. doi: 10.1164/rccm.202101-0117OC.
9
Is deployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso.仅部署诊断检测是否足够？加强结核实验室网络的综合干预包：布基纳法索的三年经验。
BMC Infect Dis. 2021 Apr 13;21(1):346. doi: 10.1186/s12879-021-06012-y.
10
Advances in clinical trial design: Weaving tomorrow's TB treatments.临床试验设计的进展：编织明天的结核病治疗方法。
PLoS Med. 2020 Feb 27;17(2):e1003059. doi: 10.1371/journal.pmed.1003059. eCollection 2020 Feb.

本文引用的文献

1
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.保持 III 期结核病临床试验的相关性：适应快速变化的格局。
PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.
2
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.药物敏感性肺结核治疗缩短方案的患者水平汇总分析。
Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5.
3
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.九个非洲国家采用短程耐多药结核病方案的治疗结果。
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17.
4
Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials.比较肺结核药物治疗方案的疗效：早期临床试验终点的荟萃分析。
Clin Infect Dis. 2017 Jul 1;65(1):46-54. doi: 10.1093/cid/cix247.
5
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.治疗结核病新药物方案的优先级设定：一种流行病学模型
PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.
6
Adaptive clinical trials in tuberculosis: applications, challenges and solutions.结核病的适应性临床试验：应用、挑战与解决方案
Int J Tuberc Lung Dis. 2015 Jun;19(6):626-34. doi: 10.5588/ijtld.14.0988.
7
Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation.确保合理引入和负责任使用新型结核病工具：欧洲呼吸学会多部门磋商的成果
Eur Respir J. 2014 Dec;44(6):1412-7. doi: 10.1183/09031936.00132114.
8
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.高剂量利福喷汀联合莫西沙星治疗肺结核
N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210.
9
A four-month gatifloxacin-containing regimen for treating tuberculosis.含加替沙星的四个月疗程治疗结核病。
N Engl J Med. 2014 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817.
10
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.多药耐药结核病患者抗结核药物标准化治疗方案的评估（STREAM）：一项随机对照试验的研究方案
Trials. 2014 Sep 9;15:353. doi: 10.1186/1745-6215-15-353.

新型结核病治疗方法研发的临床试验设计进展：呼吁创新。

Advances in clinical trial design for development of new TB treatments: A call for innovation.

机构信息

Unité Mixte Internationale TransVIHMI (UMI 233 IRD-U1175 INSERM, Université de Montpellier), Institut de Recherche pour le Développement (IRD), Montpellier, France.

Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, United States of America.

出版信息

PLoS Med. 2019 Mar 22;16(3):e1002769. doi: 10.1371/journal.pmed.1002769. eCollection 2019 Mar.

DOI:10.1371/journal.pmed.1002769
PMID:30901322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6430361/
Abstract

Christian Lienhardt and Payam Nahid launch the Collection on Advances in Clinical Trial Design for Development of New Tuberculosis Treatments.

摘要

克里斯蒂安·利恩哈特和佩亚姆·纳希德推出了《临床试验设计在开发新型结核病治疗方法方面的进展》专集。